Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYTECH : Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –February 28, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Mar. 7, 2018-- Regulatory News : ERYTECH (Euronext: ERYP- Nasdaq: ERYP) Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq
View HTML
Toggle Summary ERYTECH : Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –February 28, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Mar. 7, 2018-- Regulatory News : ERYTECH (Euronext: ERYP- Nasdaq: ERYP) Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq
View HTML
Toggle Summary ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
LYON, France and CAMBRIDGE, Mass. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first three
View HTML
Toggle Summary ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
LYON, France --(BUSINESS WIRE)--Apr. 24, 2018-- Regulatory News : ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform,
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Nov 5, 2020

Business Update and Financial Highlights for the 3rd Quarter of 2020 (after U.S. market close)

Summary Toggle Nov 6, 2020 at 8:30 AM EST

Erytech Pharma 3rd Quarter of 2020 Conference Call and Webcast

Summary Toggle Nov 17 - Nov 19, 2020

Jefferies Health Care Conference, Virtual

RECEIVE E-MAIL ALERTS

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top